OxRML/AgentSLR huggingface dataset:
Parameter: Mutations - mutation rate (Mutations)
Value: 2.4709 Mutations/site/generation (mu) (Mean)
Exponent (base 10): 0
Uncertainty: 2.3819 - 2.5546 (HPDI 95%)
Statistical approach: Estimated model parameter
Genome site: NS5; 3rd codon
Population: Persons under investigation, sex: , ages  to 
Country: Multi-country: Americas (n = 13), Asia (n = 3), Africa (n = 2), Oceania (n = 1)
Setting: Population based, 
Sample size: 108
Study period: 1947 - Oct 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 25 Percentage (%) ()
Exponent (base 10): 0
Case definition: Clinically diagnosed/symptomatic
Numerator/denominator: 51 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Borno state
Setting: Hospital based, 
Sample size: 200
Study period: Mar 2018 - Apr 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 22 Percentage (%) ()
Exponent (base 10): 0
Case definition: Clinically diagnosed/symptomatic
Numerator/denominator: 30 / 137 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Nigeria
Location: Borno state
Setting: Hospital based, 
Sample size: 200
Study period: Mar 2018 - Apr 2018
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 0.2374 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Disaggregated by: Method, Other
Reproduction number method: Compartmental model Other
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Location: Amazonas
Setting: Population based, 
Study period: 6 Feb 2021 - 30 Apr 2021
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.13 No units (Unspecified)
Exponent (base 10): 0
Uncertainty: 1.61 - 2.64 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Other
Population: General population, sex: Both, ages  to 
Country: Brazil
Setting: Population based, Both urban and rural areas
Study period: Jan 2015 - Sep 2016
Parameter: Reproduction number (Basic R0) - Vector-borne (Reproduction number)
Value: 2.04 No units (Unspecified)
Exponent (base 10): 0
Uncertainty: 1.53 - 2.55 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Population: General population, sex: Both, ages  to 
Country: Brazil
Setting: Population based, Both urban and rural areas
Study period: Jan 2015 - Sep 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 5 / 384 (method: )
Seroprevalence adjustment: Naive
Population: Other, sex: Unspecified, ages  to 
Country: Uganda
Location: Nkonkonjeru
Setting: Hospital based, Unspecified
Sample size: 384
Study period: Feb 2014 - Oct 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 3 / 5 (method: )
Seroprevalence adjustment: Naive
Population: Other, sex: Unspecified, ages  to 
Country: Uganda
Location: Nkonkonjeru
Setting: Hospital based, Unspecified
Sample size: 384
Study period: Feb 2014 - Oct 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 6.66 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 5 / 75 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Female, ages  to 
Country: India
Location: Bhopal region
Setting: Unspecified, Unspecified
Sample size: 75
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 15.38 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 10 / 75 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages  to 
Country: India
Location: Bhopal region
Setting: Unspecified, Unspecified
Sample size: 75
Study period: Unspecified
Parameter: Human delay - Onset to Admission to care (Human delay)
Value: 2 Days (Median)
Exponent (base 10): 0
Uncertainty: 0 - 7 (95% CI)
Bounds: 1 - 2
Statistical approach: Observed sample statistic
Disaggregated by: Age
Population: Children, sex: Both, ages 0 to 18
Country: United States
Location: Ponce, Puerto Rico
Setting: Hospital based, Unspecified
Sample size: 351
Study period: 2012 - 31 Dec 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 4.3 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 1519 / 66 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Colombia
Setting: Population based, Unspecified
Sample size: 1519
Study period: Feb 2017 - Mar 2019
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 9 / 1080 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages  to 
Country: Colombia
Setting: Population based, Unspecified
Sample size: 1108
Study period: Feb 2017 - Mar 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 21.7 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 23 / 106 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Unspecified, ages  to 
Country: Sudan
Setting: Population based, Unspecified
Sample size: 106
Study period: Dec 2012 - Jan 2013
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3.2 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 3 / 92 (method: )
Seroprevalence adjustment: Naive
Population: Other, sex: Unspecified, ages  to 
Country: Sudan
Setting: Population based, Unspecified
Sample size: 92
Study period: Dec 2012 - Jan 2013
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 0 / 223 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Population based, Both urban and rural areas
Sample size: 223
Study period: May 2021 - Oct 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 43.95 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 98 / 223 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Population based, Both urban and rural areas
Sample size: 223
Study period: May 2021 - Oct 2021
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 0 / 186 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Manaus
Setting: Population based, Both urban and rural areas
Sample size: 186
Study period: May 2021 - Oct 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 33.87 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 63 / 186 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Brazil
Location: Manaus
Setting: Population based, Both urban and rural areas
Sample size: 186
Study period: May 2021 - Oct 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 51.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 102 / 197 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: General population, sex: Both, ages 1 to 86
Country: Vanuatu
Location: Espiritu Santo
Setting: Population based, Unspecified
Sample size: 197
Study period: Aug 2016 - Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 67.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 141 / 208 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: General population, sex: Both, ages 8 to 88
Country: New Zealand
Location: Rarotonga, Cook Islands
Setting: Population based, Unspecified
Sample size: 208
Study period: Jan 2017 - Apr 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 58.3 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 35 / 60 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: General population, sex: Both, ages 16 to 80
Country: New Zealand
Location: Aitutaki
Setting: Population based, Unspecified
Sample size: 60
Study period: Jan 2017 - Apr 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 34 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 27.4 - 40.6 (95% CI)
Numerator/denominator: 68 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 0 to 83
Country: Mali
Location: Bamba, Sibirila, Bougouni, Sikasso
Setting: Population based, Rural area
Sample size: 200
Study period: Feb 2015
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 24.5 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 18.5 - 30.5 (95% CI)
Numerator/denominator: 49 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 0 to 83
Country: Mali
Location: Banzana, Sibirila, Bougouni, Sikasso
Setting: Population based, Rural area
Sample size: 200
Study period: Feb 2015
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 19 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 13.6 - 24.4 (95% CI)
Numerator/denominator: 38 / 200 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 0 to 83
Country: Mali
Location: Soromba, Sibirila, Bougouni, Sikasso
Setting: Population based, Rural area
Sample size: 200
Study period: Feb 2015
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 41.7 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 244 / 585 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 5 to 82
Country: Malaysia
Location: "Peninsula"
Setting: Population based, Rural area
Sample size: 585
Study period: Unspecified
Parameter: Human delay - Onset to Admission to care (Human delay)
Value: 3.3 Days (Mean)
Exponent (base 10): 0
Uncertainty: 0.98 (Standard Deviation)
Uncertainty (single): 0.98 (Standard Deviation)
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 0 to 
Country: Ecuador
Location: Portoviejo, Manabi
Setting: Hospital based, Unspecified
Sample size: 467
Study period: 1 Jan 2016 - 31 Aug 2016
Parameter: Human delay - Onset to Recovery/non-Infectiousness (Human delay)
Value: 4.5 Days (Mean)
Exponent (base 10): 0
Uncertainty: 2 - 7 (Range)
Uncertainty (single): 1.8 (Standard Deviation)
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 0 to 
Country: Ecuador
Location: Portoviejo, Manabi
Setting: Hospital based, Unspecified
Sample size: 467
Study period: 1 Jan 2016 - 31 Aug 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 22.7 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 45 / 198 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Both, ages  to 45
Country: El Salvador
Location: Sonsonate
Setting: Population based, Unspecified
Sample size: 198
Study period: Mar 2022 - Sep 2022
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 28.6 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 36 / 126 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Mexico
Location: Oaxaca
Setting: Hospital based, Unspecified
Sample size: 126
Study period: Dec 2017 - Feb 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 31 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 39 / 126 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Mexico
Location: Oaxaca
Setting: Hospital based, Unspecified
Sample size: 126
Study period: Dec 2017 - Feb 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 5.5 Percentage (%) (Central)
Exponent (base 10): 0
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages  to 
Country: Mexico
Location: Oaxaca
Setting: Hospital based, Unspecified
Sample size: 126
Study period: Dec 2017 - Feb 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 9 / 13 (method: )
Seroprevalence adjustment: Naive
Population: Children, sex: Both, ages  to 
Country: Mexico
Location: Oaxaca
Setting: Hospital based, Unspecified
Sample size: 13
Study period: Dec 2017 - Feb 2018
Parameter: Seroprevalence - NS1 BOB ELISA (Seroprevalence)
Value: 42 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 39 - 45 (95% CI)
Bounds: 17 - 66
Numerator/denominator:  / 1192 (method: )
Seroprevalence adjustment: Adjusted
Statistical approach: Estimated model parameter
Disaggregated by: Age, Other, Region, Sex
Population: General population, sex: Both, ages 2 to 60
Country: Ecuador
Location: Borbón, Maldonado, Timbiré, Santa Maria, Santo Domingo, Colon Eloy
Setting: Community based, Both urban and rural areas
Sample size: 1192
Study period: Jul 2018 - Oct 2018
Parameter: Seroprevalence - NS1 BOB ELISA (Seroprevalence)
Value: 29 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 25 - 33 (95% CI)
Bounds: 0 - 52
Numerator/denominator:  / 1126 (method: )
Seroprevalence adjustment: Adjusted
Statistical approach: Estimated model parameter
Disaggregated by: Age, Region, Sex
Population: General population, sex: Both, ages 2 to 60
Country: Ecuador
Location: Borbón, Maldonado, Timbiré, Santa Maria, Santo Domingo, Colon Eloy
Setting: Community based, Both urban and rural areas
Sample size: 1126
Study period: Aug 2019 - Oct 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 6.48 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 47 / 725 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: , sex: Both, ages  to 
Country: Pakistan
Location: Faisalabad
Setting: Population based, 
Sample size: 725
Study period: 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 6.48 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 47 / 47 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Risk factor: Age;Occupation;Sex (outcome: ; significant: ; adjusted: ; occupation: )
Population: General population, sex: Both, ages  to 
Country: Pakistan
Location: Faisalabad
Setting: Population based, 
Sample size: 725
Study period: 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.69 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 5 / 47 (method: Naive)
Seroprevalence adjustment: Naive
Population: General population, sex: Both, ages  to 
Country: Pakistan
Location: Faisalabad
Setting: Population based, 
Sample size: 725
Study period: 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 4  ()
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 2 / 50 (method: Naive)
Seroprevalence adjustment: Naive
Population: Children, sex: Both, ages 2 to 9
Country: Cambodia
Location: Kampong Speu
Setting: Other, 
Sample size: 770
Study period: Jul 2018 - Aug 2018
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.135 No units (Central)
Exponent (base 10): 0
Uncertainty: 2.07 - 2.2 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Country: Unspecified
Study period: 1 Oct 2013 - 30 Apr 2014
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 4.5537 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Population: General population, sex: , ages  to 
Country: El Salvador
Setting: Population based, 
Study period: Oct 2015 - Apr 2016
Parameter: Human delay - Exposure/Infection to Recovery/non-Infectiousness (inverse parameter) (Human delay)
Value: 0.125 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: El Salvador
Setting: Population based, 
Study period: Oct 2015 - Apr 2016
Parameter: Human delay - infectious period (inverse parameter) (Human delay)
Value:  Per day (Unspecified)
Exponent (base 10): 0
Bounds: 0.114 - 0.333
Statistical approach: Estimated model parameter
Disaggregated by: Method
Population: General population, sex: , ages  to 
Country: Brazil
Setting: Population based, 
Study period: Jan 2016 - Dec 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 5 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 2.5 - 10 (95% CI)
Numerator/denominator: 8 / 141 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages 25 to 51
Country: United States
Setting: Travel based, Unspecified
Sample size: 141
Study period: Jan 2016 - Aug 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 1 / 141 (method: )
Seroprevalence adjustment: Naive
Population: Pregnant women, sex: Female, ages 25 to 51
Country: United States
Setting: Travel based, Unspecified
Sample size: 141
Study period: Jan 2016 - Aug 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 30 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 6 / 20 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Unspecified, ages  to 14
Country: Nigeria
Location: Igbo-Ora
Setting: Population based, Unspecified
Sample size: 20
Study period: May 1975 - Oct 1975
Parameter: Human delay - First detection of anti-ZIKV IgM to Last detection of anti-ZIKV IgM (Human delay)
Value: 124 Days (Mean)
Exponent (base 10): 0
Uncertainty: 139 - 109 (95% CI)
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages 15 to 70
Country: United States
Setting: Hospital based, 
Sample size: 59
Study period: 13 Jul 2016 - 19 Sep 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0.55 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 1 / 182 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages  to 
Country: Brazil
Location: Rio Grande do Sul
Setting: Hospital based, 
Sample size: 182
Study period: 5 Dec 2016 - 6 Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 22.4 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 34 / 152 (method: )
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other, Region, Sex
Population: Mixed groups, sex: Both, ages 0 to 80
Country: Nigeria
Location: Abia
Setting: Hospital based, 
Sample size: 871
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 18.7 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 56 / 300 (method: )
Disaggregated by: Age, Other, Region, Sex
Population: Mixed groups, sex: Both, ages 0 to 80
Country: Nigeria
Location: Kaduna
Setting: Hospital based, 
Sample size: 871
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 18.6 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 82 / 419 (method: )
Disaggregated by: Age, Other, Region, Sex
Population: Mixed groups, sex: Both, ages 0 to 80
Country: Nigeria
Location: Nasarawa
Setting: Hospital based, 
Sample size: 871
Study period: Dec 2020 - Nov 2021
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 0 - 62.7
Disaggregated by: Age, Other, Region, Sex
Population: Mixed groups, sex: Both, ages 0 to 80
Country: Nigeria
Location: Abia, Kaduna, Nasarawa
Setting: Hospital based, 
Sample size: 871
Study period: Dec 2020 - Nov 2021
Parameter: Pregnancy loss proportion (Other transmission parameters)
Value:   (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 1 / 4 (method: Naive)
Trimester exposed: First trimester
Women or infants: women
Pregnancy outcome type: miscarriage
Population: Pregnant women, sex: Female, ages  to 
Location: Veterans Health Administration in US and Caribbean
Setting: Hospital based, 
Sample size: 4
Study period: 1 Dec 2015 - 31 Oct 2016
Parameter: Zika congenital syndrome (microcephaly) proportion (Other transmission parameters)
Value: 10 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 27 / 273 (method: Naive)
Statistical approach: Observed sample statistic
Trimester exposed: Whole pregnancy
Women or infants: women
Pregnancy outcome type: microcephaly
Population: Persons under investigation, sex: Unspecified, ages 0 to 0
Country: France
Location: French Guiana
Setting: Hospital based, Unspecified
Sample size: 291
Study period: Jan 2016 - Jul 2016
Parameter: Pregnancy loss proportion (Other transmission parameters)
Value: 4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Uncertainty: 2 - 7 ()
Case definition: Confirmed
Numerator/denominator: 12 / 291 (method: Naive)
Statistical approach: Observed sample statistic
Trimester exposed: Whole pregnancy
Women or infants: women
Pregnancy outcome type: general pregnancy loss
Population: Persons under investigation, sex: Unspecified, ages 0 to 0
Country: France
Location: French Guiana
Setting: Hospital based, Unspecified
Sample size: 291
Study period: Jan 2016 - Jul 2016
Parameter: Zika congenital syndrome (microcephaly) proportion (Other transmission parameters)
Value: 2.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 2 / 80 (method: Naive)
Statistical approach: Observed sample statistic
Trimester exposed: First trimester
Women or infants: women
Pregnancy outcome type: microcephaly
Population: Pregnant women, sex: Female, ages 0 to 0
Country: France
Location: French Guiana
Setting: Hospital based, Unspecified
Sample size: 80
Study period: 15 Jul 2016 - 1 Jan 2016
Parameter: Zika congenital syndrome (microcephaly) proportion (Other transmission parameters)
Value: 3.1 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 3 / 96 (method: Naive)
Statistical approach: Observed sample statistic
Trimester exposed: Second trimester
Women or infants: women
Pregnancy outcome type: microcephaly
Population: Pregnant women, sex: Female, ages 0 to 0
Country: France
Location: French Guiana
Setting: Hospital based, Unspecified
Sample size: 96
Study period: 15 Jul 2016 - 1 Jan 2016
Parameter: Zika congenital syndrome (microcephaly) proportion (Other transmission parameters)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 0 / 125 (method: Naive)
Statistical approach: Observed sample statistic
Trimester exposed: Third trimester
Women or infants: women
Pregnancy outcome type: microcephaly
Population: Pregnant women, sex: Female, ages 0 to 0
Country: France
Location: French Guiana
Setting: Hospital based, Unspecified
Sample size: 125
Study period: 15 Jul 2016 - 1 Jan 2016